poisar

Stocks · News reference

Why Is Silence Therapeutics Stock Skyrocketing Monday?

BenzingaVandana Singh

Silence Therapeutics (SLN) leaps 126% on a $1.3B cash acquisition by Merck KGaA at $20 per ADS. Deal expected to close Q1 2027.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Zacks Investment ResearchNa

    Stock Market News for Nov 13, 2026

    U.S. stock markets declined on Thursday with the Dow, Nasdaq, and S&P 500 each falling 0.4%. NVIDIA's CEO Jensen Huang resigned, rising Iran tensions, and expectations of a Fed rate hike pressured sentiment. Mixed Q3 earnings results were reported, with Merck missing estimates while Figure Technology and Wolverine World Wide beat expectations. Initial jobless claims increased to 200,000, and existing-home sales declined 5.5% in October.

  2. Globenewswire IncResearchandmarkets.Com

    Cell Lysis / Cell Fractionation - Global Strategic Business Report 2026: Capture the $4.5 Billion Market by 2032 | Features Competitive Intelligence on Thermo Fisher, Beckman Coulter, Bio-Rad, Qiagen and Merck

    The global cell lysis and cell fractionation market is projected to grow from $2.8 billion in 2025 to $4.5 billion by 2032, expanding at a 7% CAGR. Growth is driven by advances in biotechnology, personalized medicine, proteomics, genomics research, and biopharmaceutical development. Emerging technologies including automation, microfluidics, AI/ML integration, and single-cell analysis capabilities are reshaping the market landscape.

  3. Globenewswire IncNa

    DaltonTx appoints Melissa Landon as Chief Commercial Officer to drive commercial growth and strategic partnerships

    DaltonTx announced the appointment of Melissa Landon, Ph.D., as Chief Commercial Officer to lead commercial strategy and expand adoption of its Dalton platform across pharma, biotech, and CRO partners. Landon brings 20+ years of AI/ML experience in drug discovery, most recently from Merck KGaA/MilliporeSigma, and previously served as Chief Strategy Officer at Cyclica.